Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 53.89% is 45% above its 5-year average of 37.07%, near the high end of its 5-year range (0.00%–56.50%).
3.58% above its 12-month average of 52.03%.
Reported quarterly gross margin; no daily interpolation. Q1 FY2027 (2026-07-31): 56.50%.
GROSS MARGIN
53.89%
GROSS MARGIN AVG TTM
52.03%
GROSS MARGIN AVG 3Y
40.44%
GROSS MARGIN AVG 5Y
37.07%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.58%
CURRENT VS 3Y AVG
+33.26%
CURRENT VS 5Y AVG
+45.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+30.23%
vs the sector median at left
Kestra Medical Technologies, Ltd.
Market Cap
$1.61B
Gross Margin
53.89%
TTM Avg
52.03%
3Y Avg
40.44%
5Y Avg
37.07%
Market Cap
$1.62B
Gross Margin
51.01%
TTM Avg
55.14%
3Y Avg
57.28%
5Y Avg
56.79%
Market Cap
$1.63B
Gross Margin
66.15%
TTM Avg
69.48%
3Y Avg
67.43%
5Y Avg
67.56%
Market Cap
$1.64B
Gross Margin
87.11%
TTM Avg
89.24%
3Y Avg
90.16%
5Y Avg
89.75%
Market Cap
$1.57B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
66.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.61B | 53.89% | 52.03% | 40.44% | 37.07% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 44.77% | 42.62% | 43.56% | 44.93% |
| uniQure N.V. (QURE)vs › | $1.63B | 89.53% | 60.98% | 58.20% | 16.96% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 51.01% | 55.14% | 57.28% | 56.79% |
| Septerna Inc (SEPN)vs › | $1.63B | 99.57% | 100.00% | 75.00% | 75.00% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.63B | 66.15% | 69.48% | 67.43% | 67.56% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.64B | 87.11% | 89.24% | 90.16% | 89.75% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | 100.00% | 100.00% | 100.00% | 66.67% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 97.47% | 96.23% | 48.12% | 65.41% |
Gross Margin
53.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-07-31 | 56.50% |
| 2026-04-30 | 54.76% |
| 2026-01-31 | 52.57% |
| 2025-10-31 | 50.63% |
| 2025-07-31 | 45.69% |
| 2025-04-30 | 44.29% |
| 2025-01-31 | 43.39% |
| 2024-10-31 | 39.63% |
| 2024-07-31 | 32.86% |
| 2024-04-30 | 13.89% |
| 2024-01-31 | 10.63% |
| 2021-07-31 | 0.00% |
